The major focus of the CRE REDUCE is to translate new knowledge into health policy and practice. 

Given the ongoing treatment failures of infections and the escalation of resistance, timely translation of the findings is required. 

Our consumer team members will contribute to this process by providing feedback to the research team through the CRE REDUCE.

The centre has been designed so that all clinical practice guidelines can be translated by 2020. Translation will be facilitated by:

  • publishing clinical results and clinical practice guidelines,
  • presenting to relevant federal and state bodies and professional societies, and
  • ensuring consumer team members can share results with the community.

In vitro infection models

The findings from in vitro infection models will be combined with the new knowledge gained in clinical pharmacokinetic studies. Specifically, mechanism-based pharmacokinetic/dynamic modelling will be used to combine the mathematical models from in vitro infection models with the clinical pharmacokinetic patient data. Results will be presented at major international and national infectious diseases meetings to share the new knowledge on antimicrobial exposure - bacteria resistance effects.

Clinical pharmacokinetic studies

New knowledge gained from the clinical pharmacokinetic studies will characterise the
unique disposition of the respective study drugs in the different special patient populations. Pharmacokinetic data will be informative for clinicians caring for these patient groups and will provide baseline information on how antimicrobial exposure differs in these patients compared with ‘normal’ patients and healthy volunteers on which product information specified antimicrobial dosing has been based.

Dosing simulations will then be used to define dosing recommendations based on existing knowledge of pharmacokinetic/dynamic targets for clinical efficacy. Publishing these traditional analyses will provide early translation of new knowledge. Importantly, these results will be supplemented with new analyses based on the findings from in vitro infection models in order to define innovative doses that will maximise patient cure and minimise resistance emergence.

These results will be presented at relevant scientific meetings and consumer forums. We also aim to seek consumer input on improvements to patient care.

Development of innovative doses

Mathematical modeling will be applied in order to propose novel antimicrobial doses that prevent development of resistance. Clinical advisors and consumer advocates will be involved to advise on the feasibility, safety and convenience of the proposed dosing regimens before they are tested with therapeutic drug monitoring applications.  

Testing of innovative doses

Patient tolerability and capacity of the new innovative doses to supress antimicrobial resistance will be tested in clinical trials. Cost effectiveness of the novel antimicrobial doses will also be measured. 

Clinical trials

Targeted clinical trials will be undertaken in order to determine the effects of pharmacokinetics guided interventions on actual clinical outcomes.   

Development of clinical practice guidelines

New antimicrobial dosing guidelines for treatment of difficult infections will be developed and published through Australian and international journals and societies.The CRE REDUCE will establish a guideline development panel consisting of  CRE members, consumers, medical, nursing, allied health and general practice representatives. Relevant professional societies will be invited to comment on the new guidelines in order to optimise quality, safety and acceptability. A web-based, free-to-use short course for prescribing clinicians and new researchers will be developed and published.